Her 2 Positive Breast Cancer Clinical Trial
Official title:
Strain Imaging in Breast Cancer Patients Receiving Trastuzumab
The purpose of this research study is to evaluate the effects of the chemotherapeutic drug, Trastuzumab (Herceptin) on the heart. Trastuzumab (Herceptin) is used to treat specific types of breast cancer and is known to cause weakening of the heart. Unfortunately, little is know as to why this this happens. The investigators want to identify any factors that may lead to the early detection, treatment and prevention of the cardiotoxicity (heart problem) associated with this drug.
As a subject participating in this study the following information will be collected:
complete past medical history including age, height, and weight will be done with each
echocardiogram; blood pressure at clinic visits during treatment with trastuzumab, type of
cancer will be noted, type of chemotherapy, doses of chemotherapy, type and dose of
chemotherapy in the past, type and dose of radiation therapy received, names and doses of
cardiac medications, results of cardiac tests, results of lab tests, family history of heart
disease, and social history which will include risk factors for developing heart disease
including tobacco and alcohol use. This information will be entered into a database for the
investigators to try and detect any factors that may lead to the cardiotoxicity (heart
problem) that may be caused by Trastuzumab (Herceptin).
Any transthoracic echocardiogram (heart ultrasound) ordered will be further evaluated for
special parameters that may help to detect weakening of the heart earlier than a normal
ultrasound. An echocardiogram (heart ultrasound) is when a probe is placed on the chest and
pictures are taken using sound waves and a special camera.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06100874 -
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
|
Phase 2 |